Eli Lilly and Company (NYSE:LLY) Trading 4.7% Higher – Time to Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price traded up 4.7% during mid-day trading on Monday . The company traded as high as $1,064.45 and last traded at $1,057.3840. 4,759,020 shares were traded during trading, an increase of 40% from the average session volume of 3,406,404 shares. The stock had previously closed at $1,009.52.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo Nordisk said its next‑gen obesity drug failed to show non‑inferiority to Lilly’s tirzepatide in an 84‑week study, boosting confidence that Lilly’s products remain best‑in‑class for weight loss. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Positive Sentiment: Regulatory/product expansion: The FDA approved a four‑dose single‑patient KwikPen for Zepbound, giving patients a one‑month, multi‑dose option at the same self‑pay price — a clear convenience play that can help retention and adherence. Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen
• Positive Sentiment: Commercial rollout: Lilly launched the Zepbound KwikPen (monthly, $299 self‑pay option highlighted), which reduces friction for patients and may limit churn vs. single‑dose formats — supportive for revenue and margins. Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
• Positive Sentiment: Pipeline synergy: Lilly reported positive trial data showing Taltz (ixekizumab) plus Zepbound outperformed Taltz alone in adults with plaque psoriasis who are overweight — evidence that tirzepatide may have broader clinical synergies and uses. Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal
• Positive Sentiment: Institutional flows: Reports show hedge funds and large ETFs increased exposure to mega‑caps including Eli Lilly, which can amplify upward moves in the stock. Hedge Funds’ Mag 7, Eli Lilly Buying Spree Sparks Massive ETF Accumulation In IVV, SPY, QQQ
• Neutral Sentiment: Retention strategy: Coverage notes Lilly is betting the multi‑dose pen will improve patient retention and reduce device waste — strategically valuable but execution and payor response will determine magnitude of benefit. Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push
• Negative Sentiment: Insider/ownership notes: Publicized data show significant institutional and Endowment sales over the past quarters (large share movements by Lilly Endowment and others); heavy insider/institutional selling could be watched by investors as a potential risk factor. Eli Lilly rises as rival obesity-drug trial data strengthen tirzepatide’s edge

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research note on Thursday, February 5th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. TD Cowen boosted their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Truist Financial set a $1,281.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Daiwa Securities Group raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,228.54.

Eli Lilly and Company Stock Up 4.7%

The company has a market capitalization of $997.49 billion, a price-to-earnings ratio of 46.07, a P/E/G ratio of 1.17 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The firm’s fifty day moving average price is $1,054.83 and its 200-day moving average price is $917.84.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the previous year, the company posted $5.32 EPS. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 30.15%.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of LLY. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $30,000. Miller Global Investments LLC bought a new position in Eli Lilly and Company during the 4th quarter worth approximately $33,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the period. Finally, Dorato Capital Management bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $36,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.